← 홈

ADC · EGFR

4개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4개
ADCBiologicstaleThe Netherlands Cancer InstitutePhase 2

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

Non-Small Cell Lung Carcinoma; Advanced Non-Small Cell Squamous Lung Cancer · EGFR

#EGFR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
ADCBiologicstaleWhitehawk Therapeutics, Inc.Phase 1

HWK-007 (HWK-007)

Endometrial Cancer; Ovarian Cancer · EGFR

#EGFR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING
ADCBiologicstaleImmunoGen, Inc.Phase 1

IMGN289 (IMGN289)

EGFR Positive Solid Tumors · EGFR

#EGFR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 DISCONTINUED
ADCBiologicstaleCancer Institute and Hospital, …Phase 2

Almonertinib/Furmonertinib/Osimertinib (third-generation EGFR TKIs, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib))

Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors · EGFR

#EGFR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING